CS
REGN icon

Credit Suisse’s Regeneron Pharmaceuticals REGN Stock Holding History

Credit Suisse’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,300
Closed -$9.66M – 4192
2021
Q4 		$9.66M Buy
15,300
+500
+3% +$307K 0.01% 1528
2021
Q3 		$8.96M Sell
14,800
-3,700
-20% -$2.3M ﹤0.01% 1602
2021
Q2 		$10.3M Buy
18,500
+1,400
+8% +$709K 0.01% 1547
2021
Q1 		$8.09M Sell
17,100
-39,200
-70% -$19.1M ﹤0.01% 1723
2020
Q4 		$27.2M Buy
56,300
+20,200
+56% +$10.9M 0.01% 1002
2020
Q3 		$20.2M Buy
36,100
+19,600
+119% +$11.9M 0.01% 1023
2020
Q2 		$10.3M Hold
16,500
– – 0.01% 1280
2020
Q1 		$8.06M Sell
16,500
-49,100
-75% -$20.3M 0.01% 1280
2019
Q4 		$24.6M Hold
65,600
– – 0.02% 915
2019
Q3 		$18.2M Sell
65,600
-10,400
-14% -$3.08M 0.02% 976
2019
Q2 		$23.8M Buy
76,000
+60,700
+397% +$20.2M 0.02% 830
2019
Q1 		$6.28M Sell
15,300
-7,200
-32% -$2.96M 0.01% 1545
2018
Q4 		$8.4M Buy
22,500
+15,000
+200% +$5.49M 0.01% 1255
2018
Q3 		$3.03M Hold
7,500
– – ﹤0.01% 2041
2018
Q2 		$2.59M Hold
7,500
– – ﹤0.01% 2242
2018
Q1 		$2.58M Hold
7,500
– – ﹤0.01% 2218
2017
Q4 		$2.82M Hold
7,500
– – ﹤0.01% 2179
2017
Q3 		$3.35M Hold
7,500
– – ﹤0.01% 2111
2017
Q2 		$3.68M Hold
7,500
– – ﹤0.01% 1828
2017
Q1 		$2.91M Buy
+7,500
New +$2.78M ﹤0.01% 2074
2013
Q4 		– Sell
-76,500
Closed -$23.9M – 4686
2013
Q3 		$23.9M Buy
76,500
+51,500
+206% +$13.5M 0.02% 652
2013
Q2 		$5.62M Buy
+25,000
New +$5.82M 0.01% 1484

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Credit Suisse's REGN Position: Q1 2024 in Review

Credit Suisse reduced its Regeneron Pharmaceuticals (REGN) stake by 5.7% in Q1 2024, selling an estimated $9.51M and leaving 165,324 shares worth $159M. The position accounts for 0.15% of the portfolio, ranked #115.

Credit Suisse first reported a position in REGN in Q2 2013 and has held it in 44 quarters since. The position peaked at $271M in Q1 2021. 1,309 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

  • Credit Suisse held 165,324 shares of Regeneron Pharmaceuticals worth $159M as of Q1 2024.
  • Credit Suisse sold 10,004 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $9.51M.
  • Regeneron Pharmaceuticals made up 0.15% of Credit Suisse's portfolio in Q1 2024, its #115 holding.
  • Credit Suisse first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Regeneron Pharmaceuticals position peaked at $271M in Q1 2021.
  • 1,309 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.